Vanderbilt-Ingram Cancer Center

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment. The study, led by first author Matthew Resnick, M.D., instructor in Urologic Surgery, Vanderbilt University Medical Center, was [...]

Family history is the best predictor of risk for prostate cancer, suggesting that the disease has a strong hereditary component. Recently, a heritable mutation in the HOXB13 gene was found to predispose men of European descent to prostate cancer. Jeffrey Smith, M.D., Ph.D., associate professor of Medicine and Cancer Biology, and colleagues initiated a study [...]

A study led by investigators from Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tenn., finds that black men with prostate cancer receive lower quality surgical care than white men. The racial differences persist even when controlling for factors such as the year of surgery, age, comorbidities and insurance status. Daniel Barocas, M.D., MPH, assistant professor of Urologic [...]

Two proteins that act in opposing directions – one that promotes cancer and one that suppresses cancer — regulate the same set of genes in prostate cancer, Vanderbilt-Ingram Cancer Center researchers have found. The findings, reported recently in the Journal of Clinical Investigation, point toward potential drug targets and prognostic markers for prostate cancer. “We [...]

Prostate cancer cells metastasize mainly to bone, yet bone metastases are resistant to common therapies and are often fatal. A key receptor for the growth factor TGF-β (TβRII) is lost in the connective tissue (stroma) of most prostate cancers, but the effects of this loss on metastasis and bone lesion development are undefined. Recently in [...]

Earn up to 5.5 continuing education credits! Program Overview: This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers. Participants will learn how to implement the NCCN Guidelines recommendations into their [...]

Vanderbilt-Ingram Cancer Center cordially invites you and your guests to join us for Going for the Gold: Living Well through Cancer! Due to an overwhelming response, we have closed registration. We are thrilled to have so many people attend! Date: Saturday, June 30, 2012 Time: 9:30 a.m.-2:30 p.m. Where: Vanderbilt University Student Life Center 310 [...]

Join us on March 20 for a FREE informative evening on your health and wellness. Event is located at Vanderbilt-Ingram Cancer Center at Green Hills 3810 Bedford Avenue Suite 100 Nashville, TN 37215 6 p.m. Registration & Refreshments 6:30 p.m. Speaker 7:15 p.m. Questions & Answers Quitting tobacco is the best thing that you can [...]

The size of a man’s prostate gland may help predict the severity of cancer, with a smaller prostate being more likely to harbor serious disease. This finding by a group of Vanderbilt-Ingram Cancer Center researchers was published in the December issue of the Journal of Urology. Fourth-year medical resident Judson Davies, M.D., was first author [...]

Jadranko “Yadi” Franjic describes lymphedema symptoms and what is done during therapy to help control the swelling in the lymphatic system. Lymphedema is most common among patients who experience trauma to their lymphatic system. Examples include cancer patients undergoing lymphatic node dissection or radiation therapy and those who suffer a traumatic injury. Swelling of the [...]